Why the study?
Shifting from reactive to proactive CKM management requires an integrated care model aligning specialties around early, organ-protective interventions.
Design
Multidisciplinary expert perspective
Key result
SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.
Authors
Loading...
Requires proactive multidisciplinary coordination for CKM syndrome; extends SGLT2 inhibitors as foundational disease-modifying therapy.
Expert perspective emphasizes proactive, multidisciplinary management of CKM syndrome with SGLT2 inhibitors as foundational therapy.
Avogaro et al. (2026) studied this question. SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.